Health
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide), Foundayo (orforglipron) and retatrutide, will present new data across its cardiometabolic portfolio at the American Diabetes Association's 86th Scientific Sessions taking place June 5-8 in New Orleans. Together, these findings position Lilly to lead the next era of cardiometabolic care, with a differentiated suite of approved and investigational medicines built to expand choice for the millions living
About this update from Eli Lilly And Company
[{"type":"text","content":"Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to redefine oral incretin therapy","length":224,"tagName":"p","attribs":{}},{"type":"text","content":"New analyses of the ATTAIN program highlight Foundayo's profile in patient populations central to the future of cardiometabolic care, including women at every stage of menopause","length":181,"tagName":"p","attribs":{}},{"type":"text","content":"Pivotal Phase 3 results showed retatrutide, a first-in-class triple receptor agonist, delivered powerful results in obesity, type 2 diabetes and other complications","length":164,"tagName":"p","attribs":{}},{"type":"text","content":"INDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide), Foundayo (orforglipron) and retatrutide, will present new data across its cardiometabolic portfolio at the American Diabetes Association's 86th Scientific Sessions taking place June 5-8 in New Orleans. Together, these findings position Lilly to lead the next era of cardiometabolic care, with a differentiated suite of approved and investigational medicines built to expand choice for the millions living with obesity, diabetes and related conditions.","length":594,"tagName":"p"},{"type":"text","content":""No two patients with obesity or diabetes are alike, and their needs evolve over time. That's exactly why choice matters," said Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health. "The data we're presenting at ADA, including pivotal Phase 3 results for retatrutide and Foundayo, the only oral GLP-1 taken without food or water restrictions, demonstrate our ability to meet patients wherever they are and wherever they're headed."","length":502,"tagName":"p"},{"type":"text","content":"Lilly will also host an investor event on Saturday, June 6, at 6:00 p.m. CDT to highlight the company's cardiometabolic health portfolio and discuss key disclosures from the meeting. The event will be accessible via a live webcast on the "Webcasts & Presentations" section of Lilly's investor website. A replay will be available on the website following the e...